2.6mm切口人工晶状体植入治疗白内障合并高度近视的疗效观察

Phacoemulsification with Intraocular Lens Implantation through a 2.6 mm Incision in High Myopia

目的:观察使用MonarchⅡ折叠推注系统.通过2.6 mm角膜切口植入低度数或负度数丙烯酸脂(ActySof)折叠式人工晶状体治疗白内障合并高度近视的临床疗效。方法:对52例(68眼)白内障合并高度近视患者行超声乳化白内障吸除,使用MonarchⅡ折叠推注系统通过2.6 mm角膜切口植入低度数或负度数AcrySof折叠式人工晶状体,观察术中和术后并发症、术后视力。术后随访时间平均6个月(3～12个月)。结果:所有人工晶状体均能顺利植入眼内,没有发生人工晶状体断裂、擦痕、断襻或襻变形等情况,术中无并发症发生。术后3个月最佳矫正视力0.12—0.25者8眼(11.8％),0.3～0.5者21眼(30.9％),0.6～1.0者36眼(52.9％),大于1.0者3眼(4.4％);随访期间出现黄斑囊样水肿2眼,无出现视网膜脱离和后发性白内障者。结论:在白内障合并高度近视超声乳化吸除、低度数或负度数折叠式人工晶状体植入手术中,应用MonarchⅡ折叠推注系统可以将通常需要3.5 mm左右的切口减少为2.6 mm,是一种安全有效的方法。

Purpose :To evaluate the clinical effects of the low power and negative power acrylic foldable intraocular lens (AcrySof IOL) implatation through 2.6 mm incision. Methods:Fifty-two cases (68 eyes) cataract with high myopia were performed phacoemulsification, applied Monarch Ⅱ injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision. Intraoperative and postoperative complications, visual acuity were observed. The mean follow-up was 6 months (range, 3-12 months). Results :A11 the IOL implantation were uneventful and no IOL damage occurred. No intraoperative complications happened. During 3 months of follow-up, the corrected visual acuity was 0.12-0.25 in 8 eyes (11.8%), 0.3-0.5 in 21 eyes (30.9%), 0.6-1.0 in 36 eyes (52.9%) , more than 1.0 in 3 eyes (4.4%). Cystoid macular edema was found in 2 eyes. No retinal detachment and posterior capsular opacification were seen. Conclusion : It is safe and effective to applied Monarch Ⅱ injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision.